We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Ocular Therapeutix Inc
10 own
31 watching
Current Price
$9.44
$0.09
(0.96%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
589.9M
52-Week High
11.77500
52-Week Low
3.24500
Average Volume
1.02M
Dividend Yield
--
P/E Ratio
--
Market Capitalization589.9M52-Week High11.7750052-Week Low3.24500Average Volume1.02MDividend Yield--P/E Ratio--What does the Ocular Therapeutix Inc do?
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the United States. It markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery. The company's lead product includes DEXTENZA, which is in Phase III clinical trial for the treatment of post-surgical pain and inflammation, allergic conjunctivitis; and in Phase II clinical trial for the treatment of inflammatory dry eye disease. It is also developing OTX-TP, which is in Phase III clinical trial for glaucoma and ocular hypertension. In addition, the company has preclinical development of intravitreal depot with protein-based or small molecule drugs, including tyrosine kinase inhibitors, for the treatment of wet age-related macular degeneration and other retinal diseases. It has a strategic collaboration, option, and license agreement with Regeneron Pharmaceuticals, Inc. for the development of sustained release formulation of the vascular endothelial growth factor trap aflibercept for the treatment of wet age-related macular degeneration and other serious retinal diseases. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.
Read More
How much money does Ocular Therapeutix Inc make?
News & Events about Ocular Therapeutix Inc.
Globe Newswire
1 year ago
BEDFORD, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the ...
PR Newswire
1 year ago
AffaMed Therapeutics Announces Approval to Initiate a Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery AffaMed Therapeutics Announces Approval to Initiate a Phase 3 Registrational Clinical Trial in...
Globe Newswire
1 year ago
BEDFORD, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc.(NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fourth quarter and ...
Globe Newswire
1 year ago
All OTX-TKI treated subjects who were rescue-free at the Month 7 interim analysis remained rescue-free, extending the 73% rescue-free rate up to Month 10 CSFT and BCVA measurements at 10 months were comparable between OTX-TKI treated subjects and aflibercept treated subjects OTX-TKI continued to be ...
Globe Newswire
1 year ago
Dextenza Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over Previous Quarter and Approximately 11% Over Same Quarter of Prior Year Dextenza Net Product Revenue for the Year Ending 2022 is Estimated to be $50.2 million, Representing ...
Frequently Asked Questions
Frequently Asked Questions
What is Ocular Therapeutix Inc share price today?
Can Indians buy Ocular Therapeutix Inc shares?
How can I buy Ocular Therapeutix Inc shares from India?
Can Fractional shares of Ocular Therapeutix Inc be purchased?
What are the documents required to start investing in Ocular Therapeutix Inc stocks?
What is today’s traded volume of Ocular Therapeutix Inc?
What is today’s market capitalisation of Ocular Therapeutix Inc?
What is the 52-Week High and Low Range of Ocular Therapeutix Inc?
What percentage is Ocular Therapeutix Inc down from its 52-Week High?
What percentage is Ocular Therapeutix Inc up from its 52-Week Low?
Current Price
$9.44
$0.09
(0.96%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.